# US Chronic Kidney Disease Market

> US Chronic Kidney Disease Market Research Report: Size, Share, Trend Analysis By Diagnosis (Blood Test, Urine Test, Imaging Test, Kidney Biopsy), By Treatment (Drugs, Dialysis, Kidney Transplant), By Indication (Type 1 Or Type 2 Diabetes, High Blood Pressure, Polycystic Kidney Disease) and By End Users (Hospital & Clinics, Diagnostic Centers) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.64%
- **2024:** $ 8.2 Billion
- **2025:** $ 8.66 Billion
- **2035:** $ 15 Billion
- **Key Players:** Fresenius Medical Care (DE), DaVita Inc. (US), Baxter International Inc. (US), Amgen Inc. (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi S.A. (FR), Merck & Co., Inc. (US), AbbVie Inc. (US)

**Report ID:** MRFR/Pharma/14107-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-chronic-kidney-disease-market-15634

---

## Market Summary

## **US Chronic Kidney Disease Market Overview**

As per MRFR analysis, the US Chronic Kidney Disease Market Size was estimated at 8.06 (USD Billion) in 2023. The US Chronic Kidney Disease Market Industry is expected to grow from 8.51(USD Billion) in 2024 to 15 (USD Billion) by 2035. The US Chronic Kidney Disease Market CAGR (growth rate) is expected to be around 5.286% during the forecast period (2025 - 2035).

### **Key US Chronic Kidney Disease Market Trends Highlighted**

The US Chronic Kidney Disease (CKD) market is undergoing significant transformation driven by a combination of rising prevalence rates, increasing awareness, and advancements in treatment options. One key market driver is the growing population of patients diagnosed with CKD, which is largely due to factors such as aging demographics and the rise in conditions like diabetes and hypertension, known to contribute to kidney disease. This rise is prompting healthcare providers and policymakers to prioritize interventions that can improve patient outcomes and manage healthcare costs effectively.

Opportunities in the US CKD market are abundant, particularly in the realm of innovative therapies and technology integration.Companies have the potential to explore treatments such as novel pharmaceuticals, kidney transplantation solutions, and home dialysis options, all of which are gaining traction among both healthcare professionals and patients. There is also increasing interest in telehealth services and digital health tools that enable better patient monitoring and engagement. These opportunities align well with the ongoing shift towards value-based care, which emphasizes patient-centric approaches and improved quality of life.

Recent trends in the US CKD market highlight a growing emphasis on preventive care and early diagnosis. There has been a push for routine screening for kidney disease, especially among high-risk populations, allowing for timely intervention that can slow disease progression.Additionally, educational campaigns and community outreach programs are becoming more prominent, aiming to raise awareness of kidney health and encourage lifestyle changes. The integration of artificial intelligence and data analytics in predicting CKD risk and personalizing treatment is also emerging as a significant trend, marking a shift towards more tailored healthcare solutions.

This ongoing evolution reflects the commitment to addressing chronic kidney disease more effectively in the US and optimizing patient care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Chronic Kidney Disease Market Drivers**

### **Rising Prevalence of Chronic Kidney Disease**

The increasing prevalence of Chronic Kidney Disease (CKD) in the United States significantly drives the US Chronic Kidney Disease Market Industry. Reports from the Centers for Disease Control and Prevention (CDC) indicate that approximately 15% of adults in the US, which is around 37 million people, are estimated to have some form of CKD. This alarming statistic highlights a growing patient population that requires medical therapies, monitoring, and interventions, thereby expanding market opportunities for pharmaceutical companies and healthcare providers.

As CKD becomes more prevalent, the demand for renal replacement therapies, medications, and overall healthcare services specifically tailored to CKD patients is expected to heighten, fostering considerable growth in the US Chronic Kidney Disease Market. The market is not only influenced by the number of patients suffering from CKD but also by advancements in treatment options and better patient management strategies aimed at improving quality of life and minimizing complications associated with the disease.

### **Technological Advancements in Treatment Modalities**

Innovative technologies and advancements in treatment modalities such as dialysis and kidney transplantation are pivotal drivers of the US Chronic Kidney Disease Market Industry. Reports indicate that the use of home-based dialysis treatments has increased significantly, providing more convenience and flexibility for patients. The U.S. Renal Data System notes that as of the latest data, about 28% of dialysis patients in the US are using home dialysis, a figure that has steadily increased over the years.

This shift towards at-home therapies not only enhances patient satisfaction but also reduces costs associated with facility-based treatments. The continual investment in Research and Development (R&D) by major players in the healthcare sector further boosts this trend, leading to the continuous introduction of cutting-edge technology and improved therapeutic solutions for CKD patients.

### **Government Initiatives and Policies**

Government initiatives targeting chronic diseases, including Chronic Kidney Disease, significantly foster growth in the US Chronic Kidney Disease Market Industry. The US government has launched various programs aimed at preventive health measures and enhancing kidney health. For example, the National Kidney Foundation engages in public awareness campaigns to educate the population about CKD risk factors and the importance of early detection.

These initiatives are crucial as they facilitate early diagnosis and preventive measures, subsequently reducing the overall healthcare burden and promoting better patient outcomes.The financial support for kidney disease research and patient education advocated by the government guides the development of new treatment options, creating viable paths for market expansion.

### **Increased Awareness and Screening for CKD**

There is a notable increase in awareness and screening initiatives for Chronic Kidney Disease within the United States, significantly impacting the US Chronic Kidney Disease Market Industry. Programs introduced by healthcare organizations and advocacy groups promote the importance of regular screening and early diagnosis, as highlighted by the National Kidney Foundation, which estimates that only 10% of people with CKD are aware of their condition.

This knowledge gap is narrowing due to increased educational efforts and community outreach, ultimately leading to more diagnoses and treatment opportunities. The push for greater awareness is generating a greater demand for testing and treatment options in the CKD market, encouraging stakeholders to invest in developing effective screening tools and educational resources.

## **US Chronic Kidney Disease Market Segment Insights**

### **Chronic Kidney Disease Market Diagnosis Insights**

The Diagnosis segment of the US [Chronic Kidney Disease](../../../reports/chronic-kidney-disease-market-5744) Market has become increasingly significant as the prevalence of chronic kidney disease continues to rise among the population. Driven by factors such as the aging population, the increasing incidence of diabetes and hypertension, and advancements in diagnostic technologies, this segment plays a crucial role in early detection and management of the disease.

Blood Tests are essential as they help in assessing kidney function through parameters such as serum creatinine and blood urea nitrogen levels, making them the primary tool for initial screening and monitoring. Urine Tests, likewise, are vital as they can reveal abnormalities such as proteinuria, which is a key indicator of kidney damage, allowing for timely intervention. Imaging Tests, encompassing ultrasound and CT scans, aid in visualizing structural abnormalities within the kidneys, facilitating further investigation and treatment planning.

Kidney Biopsy remains a definitive method when a precise diagnosis is required, often employed when the etiology of kidney impairment is unclear; this invasive procedure helps in determining the underlying pathology of kidney diseases.Collectively, these diagnostic methods complement one another and provide critical insights into patient health, enabling healthcare providers in the US to formulate effective treatment plans and enhance patient outcomes. The rising adoption of advanced diagnostic modalities is likely to augment overall patient care and healthcare efficiency.

Additionally, the growing awareness and focus on preventive healthcare are driving demand for comprehensive diagnostic services in the US Chronic Kidney Disease Market. As the market continues to mature, the integration of artificial intelligence and telemedicine in diagnostic practices poses new opportunities for optimizing patient management.This spectrum of methodologies not only empowers clinicians but also educates patients, fostering a more informed approach towards kidney health, ultimately aiming to reduce healthcare costs and improve the quality of life for those affected by chronic kidney diseases.

Overall, within the context of the US Chronic Kidney Disease Market, the Diagnosis segment serves as a foundation for early intervention, therapeutic decision-making, and is a cornerstone of modern medical practice in addressing this prevalent health challenge.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Chronic Kidney Disease Market Treatment Insights**

The Treatment segment of the US Chronic Kidney Disease Market serves as a critical area for managing the growing prevalence of kidney-related disorders. With an overall market value expected to reach 8.51 USD Billion by 2024, the demand for effective treatments is supported by the increasing patient population and advancements in medical technologies. Within this segment, Drugs, Dialysis, and Kidney Transplant methods play prominent roles.

Drugs that target symptom alleviation and progression delay are crucial, given the need for long-term management strategies.Dialysis remains a backbone approach, catering to a significant portion of patients who require renal replacement therapy, and is often the primary treatment before a transplant option is considered. Additionally, Kidney Transplants represent a pivotal method, generally sought after for its potential to completely replace kidney function, thus enhancing quality of life. The interplay of these segments highlights a comprehensive approach to treatment and illustrates the dynamics of the US Chronic Kidney Disease Market, with ongoing innovations promising to enhance patient outcomes.

Furthermore, government initiatives and funding for Research and Development in this area lead to enhanced treatments options, thus influencing market growth positively.

### **Chronic Kidney Disease Market Indication Insights**

The US Chronic Kidney Disease Market is significantly influenced by various indications, with Type 1 and Type 2 diabetes, High Blood Pressure, and Polycystic Kidney Disease playing key roles. Type 1 and Type 2 diabetes are among the leading causes of chronic kidney disease, often leading to elevated healthcare costs and resource utilization. High Blood Pressure also emerges as a major contributor, as it exacerbates kidney dysfunction in many patients.

Polycystic Kidney Disease, a genetic disorder, further complicates the landscape, with a notable prevalence among the US population, leading to considerable treatment advancements.The importance of these indications is underscored by their direct correlation with the growing prevalence of chronic kidney disease, necessitating ongoing research and innovative treatment solutions.

Understanding the US Chronic Kidney Disease Market segmentation helps in addressing the unique requirements of each patient group, driving improved patient care and outcomes while informing the development and implementation of effective management strategies in the industry. The overall healthcare infrastructure in the US must adapt to these challenges, contributing to both the economic burden of chronic diseases and the opportunity for targeted therapies and preventive measures within the healthcare system.

### **Chronic Kidney Disease Market End User Insights**

The End User segment of the US Chronic Kidney Disease Market plays a pivotal role in shaping healthcare strategies and patient outcomes. Within this segment, Hospitals and Clinics are critical as they provide comprehensive care, including diagnosis, treatment, and ongoing management of chronic kidney disease. These facilities often serve as the first point of contact for patients and are equipped with specialized resources to manage complex cases effectively.

Diagnostic Centers also hold significant importance, as they offer advanced testing and monitoring services essential for early detection and ongoing assessment of kidney function.The increasing prevalence of chronic kidney disease in the United States underscores the need for these end users to enhance their services and adopt advanced technologies. As awareness around kidney health grows, both Hospitals and Clinics and Diagnostic Centers are expected to evolve, focusing on patient-centric care. This creates opportunities for innovation in treatment modalities, thereby driving further growth in the US Chronic Kidney Disease Market.

## **US Chronic Kidney Disease Market Key Players and Competitive Insights**

The US Chronic Kidney Disease Market is characterized by a diverse array of players, each vying for dominance in a landscape defined by constant innovation and strategic partnerships. Key competitive insights reveal a dynamic market environment shaped by advances in pharmaceuticals, therapeutic solutions, and technologies aimed at improving patient outcomes. Companies are increasingly focusing on tailored treatment options that address the unique needs of chronic kidney disease patients, and there is a strong emphasis on research and development to bring forth innovative therapies.

Regulatory landscapes, payer dynamics, and evolving patient demographics are crucial factors driving competition, with companies investing heavily in clinical trials and collaborations to enhance their market positions. Competitive strategies such as mergers and acquisitions, strategic partnerships, and an aggressive focus on customer engagement are also prevalent, all aimed at capturing a larger share of this growing market.

Genzyme, a notable player within the US Chronic Kidney Disease Market, has established itself as a formidable force through its innovative product offerings and comprehensive patient support services. The company boasts strong research and development capabilities, allowing it to introduce cutting-edge therapies specifically designed for the management of chronic kidney conditions. Genzyme's strengths lie in its ability to form strategic partnerships with healthcare providers and organizations, facilitating an integrated approach to patient care. Furthermore, the company actively engages in educational initiatives and patient outreach programs, enhancing its reputation and visibility within the market.

Genzyme's commitment to advancing treatment options for kidney disease patients not only reinforces its position in the industry but also demonstrates its dedication to improving overall patient outcomes across the United States.

Merck represents another significant player in the US Chronic Kidney Disease Market, bringing a wealth of experience and expertise in pharmaceuticals and biotechnology. The company has a robust portfolio of key products and services that cater specifically to the management of chronic kidney disease, including medications that target various aspects of the condition. Merck's extensive market presence is bolstered by its strong financial performance and commitment to ongoing research, which is evident through its active participation in clinical trials and collaborations with academic institutions.

The company's strengths lie in its innovative drug development pipeline and its ability to swiftly respond to market needs through agile strategic initiatives. Additionally, Merck has cemented its position in the market through strategic mergers and acquisitions that expand its capabilities and product offerings, ensuring that it remains a key player in the landscape of chronic kidney disease treatment in the United States.

### **Key Companies in the US Chronic Kidney Disease Market Include**

## **US Chronic Kidney Disease Market Industry Developments**

In recent months, the US Chronic Kidney Disease Market has seen significant developments, especially with the increasing focus on innovative therapies and technologies. Companies like DaVita and Fresenius Medical Care continue to expand their dialysis services amid rising patient needs. In September 2023, Amgen announced advancements in its drug pipeline targeting renal health, while Genzyme unveiled a new patient support program designed to enhance treatment compliance.

Furthermore, collaborations between American Renal Associates and various healthcare providers have emerged to optimize patient care pathways. In terms of market valuations, Bristol-Myers Squibb has reported considerable growth in its nephrology-related product sales, indicating a robust demand for kidney disease treatments. Notably, in February 2023, U.S. Renal Care acquired several clinics, enhancing its national footprint and service capabilities. Additionally, Baxter International launched a new home dialysis device in May 2023, contributing to the rising trend towards patient-centric care solutions.

The chronic kidney disease market is evolving swiftly, driven by technological innovations and strategic mergers, reflecting ongoing efforts to improve patient outcomes and industry competitiveness.

## **US Chronic Kidney Disease Market Segmentation Insights**

### **Chronic Kidney Disease Market Diagnosis Outlook**

### **Chronic Kidney Disease Market Treatment Outlook**

### **Chronic Kidney Disease Market Indication Outlook**

### **Chronic Kidney Disease Market End User Outlook**

## Market Drivers

### Increasing Aging Population

The chronic kidney disease market is growing due to the increasing aging population in the United States. As individuals age, the risk of developing chronic kidney disease (CKD) escalates, with studies indicating that approximately 35% of adults aged 65 and older are affected by some form of CKD. This demographic shift is likely to drive demand for renal care services and treatment options, thereby expanding the chronic kidney-disease market. Furthermore, the aging population often presents comorbidities such as diabetes and hypertension, which are significant risk factors for CKD. Consequently, healthcare providers are focusing on early detection and management strategies to address the rising incidence of CKD among older adults, which may further stimulate market growth.

### Policy and Regulatory Support

Policy and regulatory support for chronic kidney disease management is increasingly shaping the landscape of the chronic kidney-disease market. The U.S. government has implemented various initiatives aimed at improving kidney health, including the Advancing American Kidney Health initiative, which seeks to reduce the incidence of kidney failure and enhance patient care. Such policies are likely to encourage investment in kidney disease research and treatment options, thereby fostering market growth. Additionally, regulatory frameworks that promote the approval of new therapies and technologies may further stimulate innovation within the chronic kidney-disease market. This supportive environment could lead to improved patient access to care and better health outcomes.

### Rising Healthcare Expenditure

Healthcare expenditure in the United States is on the rise, which appears to be a crucial driver for the chronic kidney-disease market. In recent years, healthcare spending has increased significantly, with estimates suggesting that it could reach $6 trillion by 2027. This surge in expenditure is likely to enhance access to advanced diagnostic tools and treatment modalities for CKD, including dialysis and kidney transplantation. Additionally, increased funding for research and development in nephrology may lead to innovative therapies, thereby expanding the chronic kidney-disease market. As healthcare systems allocate more resources to manage chronic conditions, the focus on CKD is expected to intensify, potentially improving patient outcomes and driving market growth.

### Growing Awareness and Education

There is a notable increase in awareness and education regarding chronic kidney disease in the United States, which is positively influencing the chronic kidney-disease market. Public health campaigns and initiatives by organizations such as the National Kidney Foundation aim to educate the population about the risk factors and symptoms of CKD. This heightened awareness is likely to lead to earlier diagnosis and treatment, which could improve patient outcomes. Furthermore, as more individuals become informed about the importance of kidney health, there may be a corresponding increase in demand for screening and preventive measures. This trend suggests that the chronic kidney-disease market could benefit from a more proactive approach to kidney health management.

### Technological Innovations in Diagnostics

Technological innovations in diagnostics are emerging as a significant driver for the chronic kidney-disease market. Advances in biomarker discovery and imaging techniques are enabling earlier and more accurate detection of CKD. For instance, the development of point-of-care testing devices allows for rapid assessment of kidney function, which may facilitate timely intervention. Moreover, the integration of artificial intelligence in diagnostic processes is likely to enhance the accuracy of CKD assessments. As these technologies become more accessible, healthcare providers may be better equipped to manage CKD, potentially leading to an expansion of the chronic kidney-disease market. The ongoing research and development in this area suggest a promising future for diagnostic advancements.

## Future Outlook

The [Chronic Kidney Disease Market](https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744) is projected to grow at a 5.64% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment, and rising healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) Investment in AI-driven diagnostic tools for early detection Expansion of home dialysis solutions to enhance patient convenience

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Diagnosis: Blood Test (Largest) vs. Urine Test (Fastest-Growing)

The US chronic kidney-disease market displays a notable distribution among diagnosis segment values, with blood tests leading the charge. Blood tests dominate with their extensive application and efficiency in providing crucial renal function insights, thus commanding a significant market share. Urine tests, while currently smaller in comparison, are rapidly gaining traction due to their role in complementing blood test results and their ability to yield vital information about the kidneys' working condition. 

Growth trends within the diagnosis segment are marked by a push towards more comprehensive monitoring techniques. The rise in chronic kidney disease cases, coupled with the increasing awareness of kidney health, bolsters the demand for effective diagnostic tools. Additionally, technological advancements, particularly in urine test analysis and imaging technologies, are propelling the growth of these emerging diagnostic methods. As healthcare providers strive to enhance patient outcomes, these factors contribute to a shifting landscape in the US chronic kidney-disease market.

Blood Test: Dominant vs. Urine Test: Emerging

The blood test segment remains dominant in the US chronic kidney-disease market due to its established role in initial diagnosis and ongoing monitoring of kidney function. Its ability to quickly assess various biomarkers makes it invaluable to clinicians. In contrast, urine tests are positioned as an emerging alternative, increasingly utilized for their insights into the kidney's filtration capabilities and overall health. The rise of non-invasive testing and patient-centric approaches makes urine tests more appealing, especially for early detection of renal issues. Together, these segments illustrate a complementary relationship where blood tests serve as the primary diagnostic tool while urine tests enhance the diagnostic accuracy and patient management strategies.

### By Treatment: Dialysis (Largest) vs. Drugs (Fastest-Growing)

In the US chronic kidney-disease market, the treatment segment is primarily dominated by dialysis, accounting for a significant share due to its established role in managing end-stage renal disease. Dialysis offers critical support to patients and constitutes the backbone of kidney disease management, often being procured through various healthcare settings. Conversely, the drug segment is gaining traction, particularly with the advent of novel therapies aimed at slowing disease progression, though its market presence is currently lesser than that of dialysis.

Growth trends indicate a substantial shift towards early intervention and preventive care, resulting in the development of drugs tailored for chronic kidney disease management. This evolution is driven by increasing investment in R&D, rising prevalence of kidney diseases, and a focus on personalized treatment approaches. Additionally, technological advancements in dialysis improve efficiency and patient comfort, further solidifying its dominant position within the market.

Dialysis (Dominant) vs. Drugs (Emerging)

Dialysis is the cornerstone of treatment in the management of chronic kidney disease, characterized by its capacity to efficiently filter waste products from the blood and remove excess fluids. This modality is crucial for patients with end-stage renal failure, making it the dominant force in the treatment segment. On the other hand, the drugs segment is emerging rapidly with innovative therapies aimed at delaying disease progression and reducing complications associated with kidney diseases. These new drugs are increasingly recognized for their potential to transform treatment paradigms, contributing to a holistic approach to kidney care. As healthcare providers transition towards integrating pharmacological therapies, the balance between dialysis and drug therapies is expected to evolve significantly.

### By Indication: High Blood Pressure (Largest) vs. Type 2 Diabetes (Fastest-Growing)

In the US chronic kidney-disease market, High Blood Pressure represents the largest segment due to its strong association with kidney dysfunction, affecting a significant portion of the population. Type 2 Diabetes, while smaller in share, is rapidly gaining attention as a critical risk factor for chronic kidney disease progression. Polycystic Kidney Disease, though important, maintains a smaller presence in comparison to these two major segments.

Growth trends indicate that the prevalence of Type 2 Diabetes is accelerating, driven by rising obesity rates and lifestyle choices. Concurrently, High Blood Pressure remains a dominant contributor due to increasing stress and dietary factors. As awareness of the link between these conditions and chronic kidney disease grows, targeted treatments are expected to thrive, driving market demand.

High Blood Pressure (Dominant) vs. Type 2 Diabetes (Emerging)

High Blood Pressure is established as the dominant segment in the US chronic kidney-disease market, reflecting its widespread impact on kidney health through mechanisms such as damage to blood vessels. Patients with uncontrolled blood pressure often experience deterioration of kidney function, leading to increased healthcare costs and complications. In contrast, Type 2 Diabetes is emerging rapidly as a critical segment, propelled by rising rates of obesity and sedentary lifestyles. The link between diabetes and kidney disease is increasingly recognized, prompting healthcare providers to prioritize management strategies for diabetic patients to mitigate kidney risks. Both segments present unique challenges and opportunities, emphasizing the importance of integrated care approaches for optimal patient outcomes.

### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US chronic kidney-disease market, Hospitals & Clinics hold a significant market share, serving as primary care locations where patients receive comprehensive treatment for kidney-related conditions. These facilities often provide a range of services, including dialysis, which enhances their dominance in the market. In contrast, Diagnostic Centers are increasingly gaining traction due to their focused services on early detection and monitoring of chronic kidney disease, thus attracting more patients seeking specialized care.

As healthcare trends evolve towards early intervention and preventive care, Diagnostic Centers are positioned as the fastest-growing segment within the market. The increasing awareness of chronic kidney disease and advances in diagnostic technology drive this growth. Patients are more inclined to seek specialized diagnostic tests, which creates additional demand for these centers, making them a vital component of the healthcare ecosystem addressing kidney health.

Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals & Clinics are the dominant players in the US chronic kidney-disease market, equipped with comprehensive facilities that offer a wide array of treatment options and specialized care for patients with kidney disease. They benefit from established patient relationships, enhanced trust, and integrated care offerings that encompass dialysis and nephrology services. Conversely, Diagnostic Centers are emerging as critical players focused on early detection and patient monitoring, utilizing advanced imaging and testing technologies to improve health outcomes. Their growth is supported by a rising emphasis on preventive healthcare, driving demand for more specific and frequent testing, ultimately positioning them as essential partners in the kidney care continuum.

## Competitive Benchmarking

The chronic kidney-disease market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Fresenius Medical Care (DE), DaVita Inc. (US), and Baxter International Inc. (US) are actively engaged in enhancing their operational capabilities. Fresenius Medical Care (DE) emphasizes innovation in dialysis technologies, while DaVita Inc. (US) focuses on expanding its service offerings through strategic partnerships with healthcare providers. Baxter International Inc. (US) is investing in digital health solutions to improve patient outcomes. Collectively, these strategies contribute to a dynamic competitive environment where companies are vying for leadership through technological advancements and enhanced service delivery.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation and improves patient care. The collective influence of these major players is significant, as they set industry standards and shape market trends through their strategic initiatives.
In October DaVita Inc. (US) announced a partnership with a leading telehealth provider to integrate remote monitoring solutions into its patient care model. This strategic move is likely to enhance patient engagement and improve health outcomes by allowing for real-time data collection and analysis. Such integration of technology into traditional care models reflects a broader trend towards digital transformation in the healthcare sector, positioning DaVita as a forward-thinking leader in chronic kidney disease management.
In September Baxter International Inc. (US) launched a new home dialysis system designed to improve patient convenience and comfort. This product introduction is significant as it aligns with the growing demand for home-based therapies, particularly in [chronic disease management](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981). By focusing on patient-centric solutions, Baxter is not only expanding its product portfolio but also addressing the evolving needs of patients, which could enhance its competitive edge in the market.
In August Fresenius Medical Care (DE) expanded its research and development efforts by investing €50 million in a new innovation center dedicated to kidney health. This investment underscores the company's commitment to advancing treatment options and improving patient outcomes through research. By fostering innovation, Fresenius aims to solidify its position as a leader in the chronic kidney-disease market, potentially setting new benchmarks for treatment efficacy and patient care.
As of November current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in healthcare solutions. Strategic alliances are increasingly shaping the landscape, enabling companies to leverage complementary strengths and enhance their service offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology integration, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in the rapidly changing market.

## Recent News & Developments

In recent months, the US Chronic Kidney Disease Market has seen significant developments, especially with the increasing focus on innovative therapies and technologies. Companies like DaVita and Fresenius Medical Care continue to expand their dialysis services amid rising patient needs. In September 2023, Amgen announced advancements in its drug pipeline targeting renal health, while Genzyme unveiled a new patient support program designed to enhance treatment compliance.

Furthermore, collaborations between American Renal Associates and various healthcare providers have emerged to optimize patient care pathways. In terms of market valuations, Bristol-Myers Squibb has reported considerable growth in its nephrology-related product sales, indicating a robust demand for kidney disease treatments. Notably, in February 2023, U.S. Renal Care acquired several clinics, enhancing its national footprint and service capabilities. Additionally, Baxter International launched a new home dialysis device in May 2023, contributing to the rising trend towards patient-centric care solutions.

The chronic kidney disease market is evolving swiftly, driven by technological innovations and strategic mergers, reflecting ongoing efforts to improve patient outcomes and industry competitiveness.

## Report Scope

| MARKET SIZE 2024 | 8.2(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 8.66(USD Billion) |
| MARKET SIZE 2035 | 15.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.64% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Fresenius Medical Care (DE), DaVita Inc. (US), Baxter International Inc. (US), Amgen Inc. (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi S.A. (FR), Merck & Co., Inc. (US), AbbVie Inc. (US) |
| Segments Covered | Diagnosis, Treatment, Indication, End User |
| Key Market Opportunities | Advancements in personalized medicine and digital health solutions enhance management of chronic kidney-disease. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the chronic kidney-disease market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US chronic kidney-disease market in 2024?**
A: The market valuation was $8.2 Billion in 2024.

**Q: What is the projected market valuation for the US chronic kidney-disease market by 2035?**
A: The projected valuation for 2035 is $15.0 Billion.

**Q: What is the expected CAGR for the US chronic kidney-disease market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 5.64%.

**Q: Which companies are considered key players in the US chronic kidney-disease market?**
A: Key players include Fresenius Medical Care, DaVita Inc., Baxter International Inc., and Amgen Inc.

**Q: What are the main segments of the US chronic kidney-disease market?**
A: The main segments include Diagnosis, Treatment, Indication, and End User.

**Q: What was the valuation of the Diagnosis segment in 2024?**
A: The Diagnosis segment had a valuation of $5.5 Billion in 2024.

**Q: What is the projected valuation for the Treatment segment by 2035?**
A: The projected valuation for the Treatment segment by 2035 is $15.0 Billion.

**Q: How much is the Drugs segment expected to grow from 2024 to 2035?**
A: The Drugs segment is expected to grow from $3.5 Billion in 2024 to $6.0 Billion by 2035.

**Q: What is the valuation of the End User segment in 2024?**
A: The End User segment was valued at $8.2 Billion in 2024.

**Q: Which indication has the highest projected growth in the US chronic kidney-disease market?**
A: High Blood Pressure is projected to grow from $3.0 Billion in 2024 to $5.5 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-chronic-kidney-disease-market-15634*